Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional tools to prevent and treat HIV-1 are therefore necessary. The identification of potent and broadly neutralizing antibodies (bNAbs) against HIV-1 has revolutionized the field and may prove clinically useful. Significant advances have been made in identifying broader and more potent antibodies, characterizing antibodies in preclinical animal models, engineering antibodies to extend half-life and expand breadth and functionality, and evaluating the efficacy of single bNAbs and bNAb combinations in people with and without HIV-1. Here, we review recent progress in developing bNAbs for the prevention and treatment of HIV-1.

尽管我们在预防和治疗 HIV-1 感染的能力方面取得了巨大进步，但 HIV-1 仍然是一种无法治愈的疾病，而且还没有一种高效的 HIV-1 疫苗。因此，需要额外的工具来预防和治疗 HIV-1。针对 HIV-1 的强效和广泛中和抗体 (bNAb) 的鉴定已经彻底改变了该领域，并可能证明在临床上有用。在识别更广泛和更有效的抗体、在临床前动物模型中表征抗体、设计抗体以延长半衰期并扩大广度和功能以及评估单一 bNAb 和 bNAb 组合在感染和未感染 HIV 的人群中的疗效方面取得了重大进展。 1. 在这里，我们回顾了开发用于预防和治疗 HIV-1 的 bNAb 的最新进展。